Teens and tweens with cystic fibrosis are trying to teach other teens a thing or two about social distancing as part of The Social Distance Squad, a program developed by AREA 23, an FCB Health Network company, in partnership with five leading CF nonprofits.
Chicago-based AbbVie announced plans for a strategic collaboration to develop a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator compound licensed from the Cystic Fibrosis Foundation.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium – consisting of Imperial College London and the Universities of Oxford and Edinburgh – Imperial Innovations, and Oxford BioMedica announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis.
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration approved Kalydeco (ivacaftor) for use in people with cystic fibrosis ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Concert Pharmaceuticals Inc. announced that it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals Inc. under which Vertex will acquire CTP-656.
The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
First Digestive Enzyme Cartridge Designed for Patients on Enteral Feeding December 02, 2015 07:00 AM Eastern Standard Time NEWTON, Mass.–(BUSINESS WIRE)–Alcresta Pharmaceuticals, a specialty pharmaceutical company focused […]
Recently, Vertex received approval for a new two-drug therapy called Orkambi, designed to treat 8,500 cystic fibrosis patients over the age of 12 who have the most common mutation for […]
The U.S. Food and Drug Administration approved Vertex Pharmaceutical Inc.’s cystic-fibrosis drug Orkambi, which could treat as many as 8,500 patients in the U. S. — but at a whopping […]
